AVOLYNT, INC.

Biotech · Private

remogliflozin etabonate, an SGLT2 inhibitor therapeutic for primary biliary cholangitis

Grants
$226K
1 award
Sector median: 1
Raised
—
No Form D on record
Contracts
—
No federal contracts on record
Patents
7
0 granted · 7 pending
Sector median: 2

Capital Timeline

Federal above the line · equity below · node area scaled to amount
Capital and federal award history
DateEventSourceAmount
Federal grantDepartment of Health and Human Services · Phase I · Remogliflozin Etabonate Effect on Primary Biliary Cholangitis$226,375
Federal grant · SBIR/STTR

Peer position

Biotech · 4373 companies · ranked on federal contract value
Biotech companies ranked by federal contract value
#CompanyContractsDisclosed equity
2739MIXEDLCMEDIA LLC——
2740LUCEOME BIOTECHNOLOGIES, LLC——
2741PROTEIN ENGINES LLC——
2742AVOLYNT, INC.——
2743TRIA BIOSCIENCE CORPORATION——
2744HINGEZ THERAPEUTICS, INC.——
2745BLUE RIDGE BIOSCIENCES, LLC——

Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.

Patents

USPTO · 0 granted of 7
  • Use Of SGLT2 Inhibitors To Treat Primary Billiary Cholangitisapplication
  • Use Of SGLT2 Inhibitors To Treat Primary Sclerosing Cholangitisapplication
  • Method For Treating Primary Sclerosing Cholangitisapplication
  • Use Of SGLT2 Inhibitors To Treat Primary Sclerosing Cholangitisapplication
  • Method For Treating Primary Sclerosing Cholangitisapplication
  • Compositions And Methods For Treating Metabolic Diseaseapplication
  • Use Of SGLT2 Inhibitors To Treat Primary Biliary Cholangitisapplication

Regulatory activity · Biotech

Sector-level, not company-level

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.